Stemcells Inc, is a biopharmaceutical company .The Company focuses on the discovery and development of cell-based therapeutics to treat damage to degeneration of organ systems, such as the central nervous system, liver and pancreas. The Company identifies and purifies rare stem and progenitor cells, develops methods and processes to expand and bank them as transplantable cells, and then demonstrates their safety and efficacy as therapeutic agents. The Company is conducting a Phase I clinical trial to evaluate the safety and preliminary efficacy of the Company’s product, the human neural stem cell (HuCNS-SC), as a treatment for infantile and late infantile neuronal ceroid lipofuscinosis (NCL), two forms of a group of disorders often referred to as Batten disease.